Suppr超能文献

增生性糖尿病视网膜病变患者玻璃体切除术后的抗血管生成转变。

Antiangiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy.

机构信息

Department of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

出版信息

Invest Ophthalmol Vis Sci. 2012 Oct 9;53(11):6997-7003. doi: 10.1167/iovs.12-9671.

Abstract

PURPOSE

We determined whether the concentrations of VEGF, erythropoietin, and endostatin in the vitreous are altered after vitrectomy in patient with proliferative diabetic retinopathy (PDR).

METHODS

We measured the levels of VEGF, erythropoietin, and endostatin by sandwich ELISA in vitreous samples collected from 38 eyes of 33 patients with PDR before pars plana vitrectomy (without IOL implantation) and the same 38 eyes during IOL implantation 3.1 to 25.7 (mean 6.7) months after the initial vitrectomy.

RESULTS

The mean vitreous levels of VEGF (964.5 pg/mL) and erythropoietin (1359.5 pg/mL) in the samples collected before vitrectomy were significantly higher in patients with PDR than in the control patients (0.68 and 70.7 pg/mL, respectively; P < 0.01). The levels of VEGF (292.5 pg/mL) and erythropoietin (557.9 pg/mL) in the samples from eyes with PDR collected at the time of IOL implantation were significantly lower than those collected before vitrectomy (P < 0.01). In contrast, the changes in the level of endostatin were not significant after vitrectomy. The VEGF and erythropoietin levels in the vitreous fluid from patients with PDR were correlated inversely with the interval between the initial vitrectomy and the time of the IOL implantation.

CONCLUSIONS

The significant decrease in the intravitreal concentration of VEGF and erythropoietin, and an absence of a significant change in the endostatin indicated a shift in the antiangiogenic balance in the vitreous of patients with PDR after successful vitrectomy.

摘要

目的

我们旨在确定增生型糖尿病视网膜病变(PDR)患者玻璃体中血管内皮生长因子(VEGF)、促红细胞生成素(EPO)和内皮抑素浓度在玻璃体切割术后是否发生改变。

方法

我们采用夹心酶联免疫吸附法(ELISA)检测 33 例 38 眼 PDR 患者行玻璃体切割术前(未植入人工晶状体)和首次玻璃体切割术后 3.1 至 25.7 个月(平均 6.7 个月)时同一眼内的 VEGF、EPO 和内皮抑素水平。

结果

与对照组(分别为 0.68 和 70.7pg/ml;P<0.01)相比,玻璃体切割术前 PDR 患者样本中 VEGF(964.5pg/ml)和 EPO(1359.5pg/ml)的平均玻璃体水平显著升高。在植入人工晶状体时取自 PDR 眼的样本中 VEGF(292.5pg/ml)和 EPO(557.9pg/ml)水平明显低于玻璃体切割术前(P<0.01)。相反,玻璃体切割术后内皮抑素水平变化不显著。PDR 患者玻璃体中 VEGF 和 EPO 水平与首次玻璃体切割术与植入人工晶状体时间间隔呈负相关。

结论

成功的玻璃体切割术后,PDR 患者玻璃体中 VEGF 和 EPO 浓度显著降低,而内皮抑素浓度无明显变化,表明玻璃体中抗血管生成平衡发生转移。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验